Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

67.78USD
30 Sep 2016
Change (% chg)

$-2.16 (-3.09%)
Prev Close
$69.94
Open
$70.26
Day's High
$70.38
Day's Low
$67.15
Volume
325,501
Avg. Vol
277,746
52-wk High
$110.75
52-wk Low
$50.00

ALNY.OQ

Chart for ALNY.OQ

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational... (more)

Overall

Beta: 2.52
Market Cap(Mil.): $5,810.42
Shares Outstanding(Mil.): 85.72
Dividend: --
Yield (%): --

Financials

  ALNY.OQ Industry Sector
P/E (TTM): -- 44.31 36.19
EPS (TTM): -4.24 -- --
ROI: -25.98 -0.23 13.87
ROE: -28.77 -2.85 14.78

BRIEF-Alnylam presents clinical and non-clinical data

* Presents clinical and non clinical data demonstrating continued rnai platform optimization and leadership in the development of rna-based therapeutics at 12th annual meeting of the Oligonucleotide Therapeutics Society

Sep 28 2016

BRIEF-Alnylam expands and strengthens management team as it plans for commercialization

* Alnylam expands and strengthens management team as it plans for commercialization

Sep 19 2016

BRIEF-Alnylam completes enrollment in phase 3 study with revusiran

* Alnylam completes enrollment in endeavour phase 3 study with revusiran, an investigational rnai therapeutic for patients with hereditary attr amyloidosis with cardiomyopathy (hattr-cm)

Aug 08 2016

BRIEF-Alnylam Pharma Announces New Positive Interim Phase 1 Study Results for Fitusiran

* Company updates guidance for phase 3, and now plans to start studies in early 2017

Jul 25 2016

BRIEF-Alnylam initiates Phase 1/2 clinical trial for ALN-HBV

* Alnylam initiates phase 1/2 clinical trial for ALN-HBV, an investigational RNAI therapeutic for the treatment of chronic Hepatitis B virus infection

Jul 07 2016

BRIEF-Alnylam Pharmaceuticals names David-Alexandre Gros Principal Financial Officer

* Appointed David-Alexandre Gros, M.D. Senior VP and chief business officer to serve as principal financial officer

Jun 15 2016

BRIEF-Bioxcel Corp says begins collaboration with Alnylam to discover novel RNAi therapeutic products

* Begins strategic collaboration with Alnylam to discover novel RNAi therapeutic products;financial terms of agreement were not disclosed

May 24 2016

U.S. RESEARCH ROUNDUP-International Paper, United Technologies, Republic Services

May 3 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including On Deck Capital and Ceva, on Tuesday. HIGHLIGHTS * International Paper Co : Jefferies cuts to hold from buy * Republic Services Inc : Barclays raises to overweight from equal weight * SBA Communications Corp : JP Morgan cuts to neutral from overweight * Bill Barrett Corp : Deutsche Bank cuts to hold f

May 03 2016

BRIEF-Alnylam Pharmaceuticals reports Q1 GAAP loss per share $1.21 including items

* Q1 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S

May 02 2016

Earnings vs. Estimates